Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Pilot To Generate Real World Data On Medicinal Cannabis Use

Executive Summary

Drug Science, a UK charity, is about to launch a 20,000-patient pilot project looking at the use of medicinal cannabis for conditions like chronic pain, multiple sclerosis and Tourette’s syndrome. It says a special licensing status for such products could eventually be possible.

You may also be interested in...



NHS England Tackles Barriers To Use Of Cannabis-Based Medicines

A review of barriers to the prescribing of cannabis-based medicines for children with epilepsy in England suggests that much needs to be done to generate the necessary evidence to assuage prescribers’ concerns. 

UK’s NICE Not Convinced By Cannabis-Based Medicines

New draft guidance from the health technology assessment body NICE says that more evidence is needed on cannabis-based medicines before they can be more widely used. In the meantime, it says they should not be used in chronic pain, epilepsy or spasticity in multiple sclerosis, while nabilone may be used for chemotherapy-related sickness.

NZ Plans New Medicinal Cannabis Regulatory Scheme & Agency

A new regulatory scheme for medicinal cannabis products, complete with a brand new agency, is on the cards in New Zealand, based on a strict licensing and quality control system that is intended to increase the supply of, and patient access to, such products.

Related Content

Topics

UsernamePublicRestriction

Register

PS125596

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel